Trevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Trevi Therapeutics reports transformative year with strong financial position

Trevi Therapeutics' strong performance in 2022, backed by positive trial results and financial stability, sets the stage for continued growth.
While facing challenges such as potential delays and increased expenses, Trevi's strategic planning and diverse opportunities position the company for success.
By leveraging its strengths in clinical development and upcoming data releases, Trevi aims to build scientific evidence and attract potential partners.
Overall, Trevi's focus on advancing its pipeline and showcasing trial results highlights its commitment to addressing unmet medical needs.

Trevi Therapeutics advances Haduvio trials, navigates regulatory challenges for growth

Trevi Therapeutics showcased progress in Haduvio's clinical development and financial stability despite a net loss.
The company faces challenges in dosing strategies, patent coverage, and regulatory hurdles but is poised for growth through strategic initiatives.

Trevi Therapeutics advances Haduvio in chronic cough, overcomes financial hurdles

Trevi Therapeutics is progressing with Haduvio's development in chronic cough indications
Financially, the company is managing its resources prudently and eliminating debt
Challenges persist with study delays due to supply shortages, but opportunities for growth are evident

Trevi Therapeutics advances Haduvio trials amidst financial stability

Trevi Therapeutics' financials show resilience with a focus on clinical advancements.
Challenges in trial planning and FDA outcomes require strategic navigation.
Opportunities for growth lie in upcoming trials and conference participation.
Overall, Trevi Therapeutics is positioned for continued progress and innovation.

Trevi Therapeutics advances novel cough treatments amidst financial challenges

Trevi Therapeutics is advancing innovative treatments for refractory chronic cough. Despite financial challenges, the company's strong cash position and ongoing clinical trials position it well for future growth.

Trevi Therapeutics reports Q1 loss, progresses in clinical trials

Trevi Therapeutics faces challenges with timelines for top line data in ongoing trials but holds promise in clinical development.
The company's financial performance reflects increased R&D expenses but maintains a strong cash position for future growth.

Trevi Therapeutics reports Q2 loss, advances in key trials

Trevi Therapeutics' Q2 2024 performance reflects ongoing investment in research with a net loss of $12.4 million and R&D expenses at $10 million.
Management's strategic focus on IPF and RCC trials, along with new leadership appointments and study initiations, underpin the company's commitment to therapeutic advancements.
While facing challenges like enrollment imbalances and financial pressures, Trevi Therapeutics remains poised for growth with upcoming data readouts and a strong research pipeline.

Trevi Therapeutics reports Q3 loss, eyes upcoming milestones and trials

Trevi Therapeutics is navigating increased R&D expenses, with a strong cash position and clear focus on upcoming data milestones. Analyst inquiries and ongoing trials present challenges, while opportunities lie in defining patient populations and regulatory decisions post-NDA submission.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW HAVEN, Conn. , Sept. 22, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and the treatment of prurigo nodularis (PN), today announced the pricing of its underwritten public offering of [●] shares of its common stock at a public offering price of $[●] per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase [●] shares of common stock at a price of $[●] per pre-funded warrant, for total proceeds of [approximately] $[●] million, before deducting underwriting discounts and commissions and expenses payable by Trevi.

Trevi Therapeutics Announces Pricing of $[50 Million] Public Offering

NEW HAVEN, Conn. , Sept. 22, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and the treatment of prurigo nodularis (PN), today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof).

Trevi Therapeutics Announces Proposed Public Offering

Data from full set of subjects was statistically significant for the primary efficacy endpoint of daytime cough frequency reduction (p

Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Presentation will be held on Monday, September 12, 2022, from 10:30 a.m. to 11:00 a.m.

Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Agile Therapeutics

Baudax Bio

Clarus Therapeutics Holdings

Nine Energy Service

Quanergy Systems

Revelation Biosciences

Alaunos Therapeutics

Mammoth Energy Services

Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).

These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)

The event will feature presentations from experts Dr. Peter Dicpinigaitis, MD, and Dr. Brian Kim, MD, MTR Virtual event to be held on Monday, September 19 th from 10 AM – 12:30 PM ET NEW HAVEN, Conn. , Aug. 30, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced that it will host a virtual R&D Day on Monday, September 19, 2022, from 10:00 AM to 12:30 PM Eastern Time.

Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022

Late-breaker abstract accepted for oral presentation on the interim analysis of cough in patients with idiopathic pulmonary fibrosis (IPF) at the upcoming European Respiratory Society International Congress 2022, Barcelona, Spain, September 4-6 Late-breaker abstract accepted for oral presentation on topline data for the treatment of prurigo nodularis (PN) at upcoming 31st European Academy of Dermatology and Venereology Congress, Milan, Italy, September 7-10 NEW HAVEN, Conn. , Aug. 24, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced two late-breaking abstracts were accepted for presentation at upcoming fall medical conferences.

Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release

Phoenix, Arizona--(Newsfile Corp. - August 22, 2022) - The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (NASDAQ: TRVI) ("the Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF). President and CEO of the Company, Jennifer Good, joined Stock Day host Sever Copley.

Trevi Therapeutics, Inc. Discusses Commercialization for Its Investigational Therapy, Haduvio, with The Stock Day Podcast

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Officer Conference Call Participants Annabel Samimy – Stifel Serge Belanger – Needham & Company Leland Gershell – Oppenheimer Nathan Weinstein – Aegis Operator Good afternoon, and welcome to the Trevi Therapeutics Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2022 Results - Earnings Call Transcript

Reported positive results from the Phase 2b/3 PRISM trial of Haduvio™ in the treatment of Prurigo Nodularis Completed a $55 million private placement Data from the full set of subjects in the completed Phase 2 CANAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF) expected in the third quarter of 2022 Management to host a conference call and webcast today at 4:30 p.m. EDT NEW HAVEN, Conn.

Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

NEW HAVEN, Conn. , Aug. 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced it will be presenting at the following investor and medical meeting conferences: Senior management at Trevi Therapeutics will be presenting at August investor and medical meeting conferences Stifel Biotech Executive Summer Summit (In-person) Date: Tuesday, August 16, 2022 Fireside chat presentation: Jennifer Good, President and CEO Time: 9:00 AM ET The fireside chat is an invitation-only event and will be available to attending participants.

Trevi Therapeutics to Present at Upcoming August Conferences

Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.

Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022

Diana Shipping

Eltek

Pangaea Logistics Solutions

Romeo Power

These penny stocks can be of significant value in the long run due to their growth prospects and innovation. The post 5 Penny Stocks to Buy on the Dip appeared first on InvestorPlace.

5 Penny Stocks to Buy on the Dip

NEW YORK, NY / ACCESSWIRE / July 14, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Trevi Therapeutics. Mark Roberts, Senior Editor at Traders News Source had the opportunity to conduct the interview featuring Jennifer Good Chief Executive Officer at Trevi Therapeutics.

Traders News Source Senior Editor Mark Roberts Interviews Jennifer Good CEO of Trevi Therapeutics

NEW HAVEN, Conn. , July 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that senior management will be attending The Twelfth London International Cough Symposium being held in London and virtually from July 13 th – 14th.

Trevi Therapeutics to Attend the Twelfth London International Cough Symposium (12th LICS)

Yesterday Trevi Therapeutics Inc's (NASDAQ: TRVI) Phase 2b/3 trial (PRISM) evaluating Haduvio (nalbuphine ER) for prurigo nodularis (PN) successfully met the key primary and secondary endpoints.  Needham writes that Haduvio had a quick onset of action, reaching stat sig at.

Why Did Needham Lift Price Target For Trevi?

Dermata Therapeutics

Yatsen Holding

Check these three penny stocks out for your watchlist right now The post Trending Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trending Penny Stocks to Add to Your Watchlist Right Now

Trevi Therapeutics (TRVI) stock is flying higher Wednesday following the release of positive trial data for its skin disease treatment. The post Trevi Therapeutics (TRVI) Stock Spikes 20% on Positive Clinical Data appeared first on InvestorPlace.

Trevi Therapeutics (TRVI) Stock Spikes 20% on Positive Clinical Data

Trevi Therapeutics (TRVI) stock is flying higher Wednesday following the release of positive trial data for its skin disease treatment! The post Trevi Therapeutics (TRVI) Spikes 20% on Positive Clinical Data appeared first on InvestorPlace.

Trevi Therapeutics (TRVI) Spikes 20% on Positive Clinical Data

Brickell Biotech Inc

NeuroSense Therapeutics Ltd

Penny stocks to buy or avoid right now? You decide after seeing the latest updates from 3 companies.

3 Penny Stocks To Watch After GDP Report

Trevi Therapeutics Inc (NASDAQ: TRVI) has announced positive results from its Phase 2b/3 PRISM trial of Haduvio in treating prurigo nodularis, a chronic disease characterized by severe pruritus and the presence of nodules, lesions, and excoriations.  In the trial, results.

Why Trevi Therapeutics Shares Trading Higher Today?

Shares of Trevi Therapeutics Inc. TRVI, +1.00% jumped 38.1% in premarket trading on Wednesday after the company said its experimental treatment for prurigo nodularis, a type of inflammatory skin disease, met the primary endpoint in a Phase 2b/3 clinical trial. If approved, the oral treatment would be the first therapy to treat prurigo nodularis, Trevi said.

Trevi's stock gains 38% after announcing positive data for skin-disease drug

Haduvio (oral nalbuphine ER) demonstrated statistically significant results on the primary efficacy endpoint as measured  by a 4-point reduction in the Worst Itch – Numerical Rating Scale (WI-NRS) (p=0.0157) The trial also met key secondary endpoints, with a safety profile consistent with prior studies Topline data will be presented by management and study investigator, Jennifer L Parish, MD, on a conference call and webcast on June 29, 2022, at 8:30 am EDT NEW HAVEN, Conn. , June 29, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced positive results from its Phase 2b/3 P ruritus R elief through I tch- S cratch M odulation (PRISM) trial of Haduvio in treating prurigo nodularis.

Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis

NEW HAVEN, Conn. , June 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that Jennifer Good, President and CEO, will deliver a company presentation at 2022 BIO International Convention.

Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Officer Conference Call Participants Serge Belanger – Needham & Company Annabel Samimy – Stifel Nathan Weinstein – Aegis Capital Operator Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

News for Trevi Therapeutics Inc Stock (TRVI)